Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providers
Hematology & Oncology Physician in Tampa, FL
NPI: 1174767917Primary Practice Location
ST ANTHONYS HOSPITAL
1200 7th Ave N, St Petersburg, FL
Primary Employer
Baycare Medical Group, Inc.
baycare.org
HQ Phone
Get M.D. Ahmad's Phone Numberphone_androidMobile
Get M.D. Ahmad's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardFL State Medical License
FL State Medical License
2015 - 2027
NY State Medical License
2013 - 2016
CT State Medical License
2012 - 2013
American Board of Internal Medicine
Hematology
American Board of Internal Medicine
Medical Oncology
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)
Fellowship • Hematology and Medical Oncology
2012 - 2015
Stony Brook Medicine/University Hospital
Residency • Internal Medicine
2009 - 2012
St. George's University School of Medicine
Medical School
Until 2009
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 345 | 569 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 249 | 708 |
| 3 | 99213Established patient office or other outpatient visit, typically 15 minutes | 177 | 227 |
| 4 | 99223Initial hospital inpatient care, typically 70 minutes per day | 166 | 193 |
| 5 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 146 | 448 |
Authors: Don Eslin, Panida Sriaroon, Zeinab Afify, John Bohnsack, Jolan Walter, Emma Westermann-Clark, Irmel Ayala
Journal: J Clin Immunol
Publication Date: 2024-01-17
Authors: Don Eslin, Panida Sriaroon, Zeinab Afify, John Bohnsack, Priya Patel, Sonia Joychan, Jolan Walter, Emma Westermann-Clark, Irmel Ayala
Journal: J Clin Immunol
Publication Date: 2024-02-29
Lead Sponsor: Alliance for Clinical Trials in Oncology
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: Questionnaire Administration, OTHER: Quality-of-Life Assessment, DRUG: Fluorouracil, DRUG: Bevacizumab, DRUG: Oxaliplatin, DRUG: Irinotecan, DIETARY_SUPPLEMENT: Cholecalciferol, DRUG: Irinotecan Hydrochloride, DRUG: Leucovorin Calcium
Lead Sponsor: Alliance for Clinical Trials in Oncology
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: Placebo, OTHER: Laboratory Biomarker Analysis, OTHER: Quality-of-Life Assessment, DRUG: Naloxegol
Lead Sponsor: SWOG Cancer Research Network
Collaborators: National Cancer Institute (NCI), Cancer Prevention Pharmaceuticals, Inc.
Intervention / Treatment: DRUG: Eflornithine plus sulindac, DRUG: Eflornithine placebo & sulindac placebo, DRUG: eflornithine & sulindac placebo, DRUG: Eflornithine placebo & sulindac
